On Oct 24, major Wall Street analysts update their ratings for $CME Group (CME.US)$, with price targets ranging from $181 to $258.
BofA Securities analyst Craig Siegenthaler maintains with a sell rating, and adjusts the target price from $180 to $181.
Citi analyst Christopher Allen maintains with a buy rating, and adjusts the target price from $250 to $255.
Barclays analyst Benjamin Budish maintains with a hold rating, and adjusts the target price from $209 to $231.
Oppenheimer analyst Owen Lau maintains with a buy rating, and adjusts the target price from $245 to $258.
RBC Capital analyst Ashish Sabadra maintains with a hold rating, and maintains the target price at $235.
Furthermore, according to the comprehensive report, the opinions of $CME Group (CME.US)$'s main analysts recently are as follows:
The company experienced an 'exceptional quarter.' Although the stock reaction was subdued due to already lofty expectations and the absence of updates on the capital return strategy, the additional details provided during the earnings call were seen as clear positives. The risk/reward profile for the company remains favorable.
Following the Q3 report, it's noted that management expressed optimism regarding the expansion in the retail sector, and placed emphasis on the significant growth originating from international markets.
CME Group reported a record quarter, with Q3 adjusted earnings per share surpassing both the anticipated figures and the consensus estimates. The heightened uncertainty surrounding the U.S. election and the global political climate has spurred a greater need for risk management solutions, serving as a positive influence for CME's business.
Here are the latest investment ratings and price targets for $CME Group (CME.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月24日，多家華爾街大行更新了$芝加哥商品交易所 (CME.US)$的評級，目標價介於181美元至258美元。
美銀證券分析師Craig Siegenthaler維持賣出評級，並將目標價從180美元上調至181美元。
花旗分析師Christopher Allen維持買入評級，並將目標價從250美元上調至255美元。
巴克萊銀行分析師Benjamin Budish維持持有評級，並將目標價從209美元上調至231美元。
奧本海默控股分析師Owen Lau維持買入評級，並將目標價從245美元上調至258美元。
加皇資本市場分析師Ashish Sabadra維持持有評級，維持目標價235美元。
此外，綜合報道，$芝加哥商品交易所 (CME.US)$近期主要分析師觀點如下：
公司經歷了一個「非同尋常的季度」。儘管股票市場反應平淡，原因是預期過高，也因爲尚未更新資本回報策略，但在業績會上提供的額外細節被視爲明顯的積極因素。該公司的風險/回報概況仍然有利。
根據第三季度報告，管理層表示對零售板塊擴張感到樂觀，並強調來自國際市場的顯著增長。
芝加哥商品交易所報告顯示，第三季度調整後每股收益達到創紀錄水平，超過了預期數和共識預測。圍繞美國選舉和全球政治氛圍加劇的不確定性增加了對風險管理解決方案的需求，這對cme的業務產生了積極影響。
以下爲今日5位分析師對$芝加哥商品交易所 (CME.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
